Assisted Reproductive Technology Market Research Report – Forecast to 2027

Assisted Reproductive Technology Market Report, by Diagnosis (Ovulation Testing, Hysterosalpingography), Type (Ovulation Induction, Artificial Insemination, Surrogacy), End-User (Hospitals & Clinics, IVF Center)- Forecast Till 2027

ID: MRFR/LS/4898-HCR | February 2021 | Region: Global | 90 pages

Assisted Reproductive Technology Market Scenario


The reproductive technology such as fertility medication, in vitro fertilization and surrogacy used to treat infertility among the women, is termed as assisted reproductive technology. The causes of infertility in women may be ovulation disorders, uterine or cervical abnormalities, fallopian tube damage or blockage, endometriosis, cancer and others. It may also be caused due to lifestyle factors like smoking tobacco or marijuana, alcohol consumption, overweight, lack of physical inactivity. Global assisted reproductive technology market size is expected to grow at a CAGR of ~10% over the forecast period


 The assisted reproductive technology market is expected to witness a tremendous growth owing to the rising prevalence of infertility. Other key factors such as the growing obesity among women, increase in ovulation disorders, change to sedentary lifestyle, growing consumption of unhealthy diet, increasing occurrence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence ovarian and endometrial cancer, increase in smoking and alcohol consumption are contributing towards the growth of the reproductive medicine market. According to the Office on Women's Health 2012, around 6.1 million women of age 15-44 years in the US are unable to conceive. Such a high incidence of infertility is expected to drive the market growth during the forecast period.


However, factors such as lower success rate, the high cost of assisted reproductive technology procedures, expensive treatments, raising ethical issues, chances of birth defects, the risk of prematurity and low birth weight in newborn and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.


Assisted Reproductive Technology Market Segmentation


The assisted reproductive technology market has been segmented on the basis of diagnosis, type, end-user.


On the basis of diagnosis, the market assisted reproductive technology market has been classified as ovulation testing, hysterosalpingography and other.


On the basis of technique type, the market is classified into ovulation induction, artificial insemination, surrogacy and others.


On the basis of end-user, the market is divided hospitals & clinics, IVF center and others


On the basis of region, the global assisted reproductive technology market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Assisted Reproductive Technology Market-Key players


Some of the key players in the global assisted reproductive technology market are Cosmos Biomedical Limited, California Cryobank, Bloom IVF Centre, Cryolab Ltd., Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Cooper Surgical, Inc, Ferring Pharmaceuticals, European Sperm Bank, Irvine Scientific and Hamilton Throne Ltd.


Assisted Reproductive Technology Market Regional Market Summary


It is estimated that Europe dominated the global assisted reproductive technology market owing to the increasing innovations in clinical practice and access to fertility treatment in this region. According to the Human Fertilization and Embryology Authority UK in 2016, there were 68,000 IVF treatment cycles, resulting in 20,028 births through IVF treatment. Thus, the increasing infertility treatments in this region influences the growth of this market in this region. 


North America stood second in the assisted reproductive technology (ART) market owing to the rising prevalence of obesity. Obesity affects fertility rate as it causes hormonal imbalances and problems with ovulation, thus women who suffer from obesity have fewer chances of conceiving. Obesity in males also affects the sperm count and sperm quality thus increasing male infertility. According to the National Health and Nutrition Examination Survey (NHANES), 2014, 70.2% of the total U.S. adults were overweight. Other factors such as increasing healthcare expenditure and increasing technological advancements in assisted reproductive technology (ART) drive the market growth in this region.


Asia-Pacific was projected to be the fastest growing region for the global assisted reproductive technology market in 2017. The market is expected to witness growth owing to the rising prevalence of infertility in women, changing lifestyle, and growing obesity within the population. According to the United Nations report in 2013, the main factor for low fertility in Asia is a postponement of marriage and delayed childbearing. 


The Middle East and Africa holds the least share in the global assisted reproductive technology market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the development of infertility treatment and increased numbers of IVF centers in this region. Also, governmental support, partial or full insurance coverage of treatment cost, social and religious values of childbearing and the role of children in family stability in the Middle East influence the assisted reproductive technology devices market growth in this region.


Assisted Reproductive Technology Market Segmentation


Global Assisted Reproductive Technology Market, by Diagnosis



  • Ovulation Testing

  • Hysterosalpingography

  • Ovarian Reserve Testing

  • Genetic Testing

  • Other hormone testing

  • Imaging tests


Global Assisted Reproductive Technology Market, by Type



  • Ovulation Induction (OI)

  • Artificial Insemination (AI)

  • Donor Conception

  • In-Vitro Fertilization (IVF)

  • Gamete Intrafallopian Transfer (GIFT)

  • Intracytoplasmic Sperm Injection (ICSI)

  • Preimplantation Genetic Diagnosis (PGD)

  • Surrogacy


Global Assisted Reproductive Technology market, by End-User



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Diagnostic Centers

  • Gynecology Centers

  • Feminist Health Centers

  • IVF Centers


Global Assisted Reproductive Technology Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant value
  CAGR   2018-2027: ~10%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Type, and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Some of the key players in the global assisted reproductive technology (ART) market are Cosmos Biomedical Limited, California Cryobank, Bloom IVF Centre, Cryolab Ltd., Parallabs, OvaScience, Anecova, Origio, Microm Ltd., Merck KGaA, Cooper Surgical, Inc, Ferring Pharmaceuticals, European Sperm Bank, Irvine Scientific and Hamilton Throne Ltd
  Key Market Opportunities   Innovations in clinical practice and access to fertility treatment
  Key Market Drivers

  • Growing obesity among women
  • Increase in ovulation disorders
  • Change to sedentary lifestyle
  • Growing consumption of unhealthy diet
  • Increasing occurrence of polycystic ovarian syndrome (pcos)
  • Increasing prevalence ovarian and endometrial cancer

    		•


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The types of Assisted Reproductive Technology (ART) are Ovulation Induction, Artificial Insemination, Surrogacy.

    Europe is expected to lead the Assisted Reproductive Technology Market.

    Increasing prevalence of infertility and PCOS is boosting market growth.

    High treatment cost and certain side effects may limit market growth.

    Key competitors in the Assisted Reproductive Technology Market include Hamilton Throne Ltd, Irvine Scientific, European Sperm Bank, Ferring Pharmaceuticals, Cooper Surgical, Inc, Merck KGaA, Microm Ltd., Origio, Anecova, OvaScience, Parallabs, Cryolab Ltd., Bloom IVF Centre, California Cryobank, and Cosmos Biomedical Limited.

    Assisted Reproductive Technology Market is projected to grow at a 10% CAGR between 2018-2023.

    Assisted Reproductive Technology Market is projected to grow at a 10% CAGR between 2018-2023.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Assisted Reproductive Technology (ART) Market, by Diagnosis

    6.1 Introduction

    6.2 Ovulation Testing

    6.3 Hysterosalpingography.

    6.4 Ovarian Reserve Testing

    6.5 Genetic Testing

    6.6 Other hormone testing

    6.7 Imaging tests

    Chapter 7. Global Assisted Reproductive Technology (ART) Market, by Type

    7.1 Introduction

    7.2 Ovulation Induction (OI)

    7.3 Artificial Insemination (AI)

    7.4 Donor Conception

    7.5 In-Vitro Fertilization (IVF)

    7.6 Gamete Intrafallopian Transfer (GIFT)

    7.7 Intracytoplasmic Sperm Injection (ICSI)

    7.8 Preimplantation Genetic Diagnosis (PGD)

    7.9 Surrogacy

    Chapter 8. Global Assisted Reproductive Technology (ART) market, by End-User

    8.1 Introduction

    8.2 Hospitals & Clinics

    8.3 Ambulatory Surgical Centers

    8.4 Diagnostic Centers

    8.5 Gynecology Centers

    8.6 Feminist Health Centers

    8.7 IVF Centers

    Chapter 9. Global Assisted Reproductive Technology (ART) Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 South America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Cosmos Biomedical Limited

    11.1.1 Company Overview

    11.1.2 Type Overview

    11.1.3 Financials

    11.2.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 California Cryobank

    11.2.1 Company Overview

    11.2.2 Type Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Bloom IVF Centre

    11.3.1 Company Overview

    11.3.2 Type Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Cryolab Ltd

    11.4.1 Company Overview

    11.4.2 Type/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Parallabs

    11.5.1 Company Overview

    11.5.2 Type Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 OvaScience

    11.6.1 Company Overview

    11.6.2 Type Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Anecova

    11.7.1 Overview

    11.7.2 Type Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 Merck KGaA

    11.8.1 Overview

    11.8.2 Type Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 CooperSurgical Inc.

    11.9.1 Overview

    11.9.2 Type Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 Ferring Pharmaceuticals

    11.10.1 Overview

    11.10.2 Type Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 European Sperm Bank

    11.11.1 Overview

    11.11.2 Type Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Irvine Scientific

    11.12.1 Overview

    11.12.2 Type Overview

    11.12.3 Financials

    11.12.4 Key Developments

    11.12.5 SWOT Analysis

    11.13 Hamilton Throne Ltd

    11.13.1 Overview

    11.13.2 Type Overview

    11.13.3 Financials

    11.13.4 Key Developments

    11.13.5 SWOT Analysis

    11.14 Microm Ltd

    11.14.1 Overview

    11.14.2 Type Overview

    11.14.3 Financials

    11.14.4 Key Developments

    11.14.5 SWOT Analysis

    11.15 Others

    Chapter 12 Appendix

    LIST OF TABLES

    Table 1 Assisted Reproductive Technology (ART) Market Industry Synopsis, 2020-2027

    Table 2 Global Assisted Reproductive Technology (ART) Market Estimates & Forecast, 2020-2027, (USD Million)

    Table 3 Global Assisted Reproductive Technology (ART) Market, by Region, 2020-2027, (USD Million)

    Table 4 Global Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 5 Global Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 6 Global Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 7 North America Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 8 North America Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 9 North America Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 10 US Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 11 US Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 12 US Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 13 Canada Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 14 Canada Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 15 Canada Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 16 South America Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 17 South America Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 18 South America Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 19 Europe Assisted Reproductive Technology (ART) Market, Diagnosis, 2020-2027, (USD Million)

    Table 20 Europe Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 21 Europe Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 22 Western Europe Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 23 Western Europe Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 24 Western Europe Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 25 Eastern Europe Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table26 Eastern Europe Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 27 Eastern Europe Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 28 Asia-Pacific Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 29 Asia-Pacific Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 30 Asia-Pacific Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    Table 31 Middle East & Africa Assisted Reproductive Technology (ART) Market, by Diagnosis, 2020-2027, (USD Million)

    Table 32 Middle East & Africa Assisted Reproductive Technology (ART) Market, by Type, 2020-2027, (USD Million)

    Table 33 Middle East & Africa Assisted Reproductive Technology (ART) Market, by End-User, 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Assisted Reproductive Technology (ART) Market

    Figure 3 Market Dynamics for Global Assisted Reproductive Technology (ART) Market

    Figure 4 Global Assisted Reproductive Technology (ART) Market Share, by Diagnosis 2020

    Figure 5 Global Assisted Reproductive Technology (ART) Market Share, by Type 2020

    Figure 6 Global Assisted Reproductive Technology (ART) Market Share, by End-User, 2020

    Figure 7 Global Assisted Reproductive Technology (ART) Market Share, by Region, 2020

    Figure 8 North America Assisted Reproductive Technology (ART) Market Share, by Country, 2020

    Figure 9 Europe Assisted Reproductive Technology (ART) Market Share, by Country, 2020

    Figure 10 Asia-Pacific Assisted Reproductive Technology (ART) Market Share, by Country, 2020

    Figure 11 Middle East & Africa Assisted Reproductive Technology (ART) Market Share, by Country, 2020

    Figure 12 Global Assisted Reproductive Technology (ART) Market: Company Share Analysis, 2020 (%)

    Figure 13 COSMOS BIOMEDICAL LIMITED: Key Financials

    Figure 14 COSMOS BIOMEDICAL LIMITED: Segmental Revenue

    Figure 15 COSMOS BIOMEDICAL LIMITED: Geographical Revenue

    Figure 16 California Cryobank: Key Financials

    Figure 17 California Cryobank: Segmental Revenue

    Figure 18 California Cryobank: Geographical Revenue

    Figure 19 Bloom IVF Centre: Key Financials

    Figure 20 Bloom IVF Centre: Segmental Revenue

    Figure 21 Bloom IVF Centre: Geographical Revenue

    Figure 22 Cryolab Ltd: Key Financials

    Figure 23 Cryolab Ltd: Segmental Revenue

    Figure 24 Cryolab Ltd: Geographical Revenue

    Figure 25 OvaScience: Key Financials

    Figure 26 OvaScience: Segmental Revenue

    Figure 27 OvaScience: Geographical Revenue

    Figure 28 Parallabs: Key Financials

    Figure 29 Parallabs: Segmental Revenue

    Figure 30 Parallabs: Geographical Revenue

    Figure 31 Anecova. : Key Financials

    Figure 32 Anecova. : Segmental Revenue

    Figure 33 Anecova. : Geographical Revenue

    Figure 34 Merck KGaA: Key Financials

    Figure 35 Merck KGaA: Segmental Revenue

    Figure 36 Merck KGaA: Geographical Revenue

    Figure 37 CooperSurgical Inc.: Key Financials

    Figure 38 CooperSurgical Inc.: Segmental Revenue

    Figure 39 CooperSurgical Inc.: Geographical Revenue

    Figure 40 Ferring Pharmaceuticals: Key Financials

    Figure 41 Ferring Pharmaceuticals: Segmental Revenue

    Figure 42 Ferring Pharmaceuticals: Geographical Revenue

    Figure 46 Irvine Scientific .: Key Financials

    Figure 47 Irvine Scientific .: Segmental Revenue

    Figure 48 Irvine Scientific .: Geographical Revenue

    Figure 49 Hamilton Throne Ltd: Key Financials

    Figure 50 Hamilton Throne Ltd: Segmental Revenue

    Figure 51 Hamilton Throne Ltd: Geographical Revenue

    Figure 52 Microm Ltd: Key Financials

    Figure 53 Microm Ltd: Segmental Revenue

    Figure 54 Microm Ltd: Geographical Revenue